Trial
NCT05167409
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
University of Colorado, Denver
Collaborators
ALX Oncology Inc.; Merck Sharp & Dohme LLC; Eli Lilly and Company; Criterium, Inc.; Academic GI Cancer Consortium (AGICC)
Condition
Microsatellite Stable Metastatic Colorectal Cancer
Intervention
Evorpacept (ALX148)
Why stopped
Accrual was terminated due to safety concerns
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-22